RESUMEN
BACKGROUND: To identify the prognostic impact of treatment centralization in patients with testicular germ cell tumors (TGCT). METHODS: We used a hospital-based cancer registry data in Japan to extract seminoma and non-seminoma cases that were diagnosed in 2013, histologically confirmed, and received the first course of treatment. To compare the 5-years overall survival (OS) rates of patients stratified by institutional care volume, we performed a Cox proportional hazards regression analysis using inverse probability of treatment weighting (IPTW) method to adjust patient backgrounds. RESULTS: A total of 1767 TGCT patients were identified. The 5-years OS rates for stage II and III TGCT patients treated at low-volume institutions (< 7 cases) were significantly worse than high-volume institutions (≥ 7 cases) (91.2% vs. 83.4%, p = 0.012). Histological stratification revealed that 5-year OS rates for stage II and III seminoma patients in the low-volume group were significantly worse than the high-volume group (93.5% vs. 84.5%, p = 0.041). Multivariate OS analysis using an IPTW-matched cohort showed that institutional care volume was an independent prognostic factor (hazard ratio 2.13 [95% confidence interval: 1.23-3.71], p = 0.0072). CONCLUSION: Our results indicate that stage II and III TGCT patients experience lower survival rates at low-volume institutions and would benefit from treatment centralization.
Asunto(s)
Neoplasias de Células Germinales y Embrionarias , Seminoma , Neoplasias Testiculares , Masculino , Humanos , Pronóstico , Estadificación de Neoplasias , Japón/epidemiología , Seminoma/terapia , Seminoma/patología , Datos de Salud Recolectados Rutinariamente , Neoplasias Testiculares/patología , Neoplasias de Células Germinales y Embrionarias/terapia , HospitalesRESUMEN
BACKGROUND: Primary mediastinal GCT (PMGCT) is a rare entity and comprises 10-15% of all mediastinal tumors. We present our institutional experience of MGCT treated with multimodality management. MATERIALS AND METHODS: We conducted a retrospective analysis between 2010 to 2020 of all mediastinal germ cell tumors registered at our center. Data on patient demographics, treatments received, treatment toxicities and response were recorded. Overall survival and relapse free survival were estimated using Kaplan-Meier methods. RESULTS: A total of 30 patients were identified. The median age was 25.5 (range, 18-45) years. Common presenting features included cough (70%) and shortness of breath (70%). Histology wise, 60% patients were non seminomatous histology, whereas 33.3% patients were Seminoma. Twenty-seven (90%) patients received chemotherapy as the first-line treatment, of whom five patients (16.6%) underwent surgery and radiation therapy subsequently. Median follow-up was 26.9 months. Thirteen patients (43.3%) had complete response (43.3%) and eight patients had partial response (26.7%), while three patients (5.5%) had progressive disease. Three-year relapse-free survival rate was 69.6% (95% confidence interval [CI], 42.8-85.6%). Overall survival (OS) at 3 years was 73.4% (95% CI, 49.4-87.3%). Patients with seminoma had a 3 year OS of 90.0% (95% CI, 47.3-98.5%) compared to those with non-seminoma (63.53% [95% CI, 32.3-83.3%]). CONCLUSIONS: Multiagent chemotherapy is the backbone of treatment in PMGCT. Seminomatous PMGCT have excellent prognosis, while further improvement is needed in those with nonseminomatous tumor.
Asunto(s)
Neoplasias del Mediastino , Neoplasias de Células Germinales y Embrionarias , Seminoma , Neoplasias Testiculares , Masculino , Humanos , Adulto , Neoplasias del Mediastino/terapia , Estudios Retrospectivos , Recurrencia Local de Neoplasia , Neoplasias de Células Germinales y Embrionarias/terapia , Seminoma/terapiaRESUMEN
BACKGROUND: According to the 2017 WHO classification, therapy related myeloid neoplasms refer to therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndromes, and therapy-related myelodysplastic/ myeloproliferative neoplasms, which happen as a belated occurring complication of chemotherapy and/or radiation therapy due to prior iatrogenic exposure of mutagenic agents. RESULTS: Herein, we present a very rare case of bone marrow metastasis from testicular seminoma coexisting with treatment-associated acute myeloid leukemia. CONCLUSIONS: This paper highlights the rare and easily misdiagnosed morphological feature of bone marrow. In these situations, clinical history, scrupulous examination of blood and bone marrow smears, immunophenotyping, and bone marrow biopsy are necessary to establish a correct diagnosis.
Asunto(s)
Neoplasias de la Médula Ósea , Leucemia Mieloide Aguda , Síndromes Mielodisplásicos , Seminoma , Neoplasias Testiculares , Humanos , Leucemia Mieloide Aguda/terapia , Masculino , Seminoma/complicaciones , Seminoma/terapia , Neoplasias Testiculares/complicaciones , Neoplasias Testiculares/terapiaRESUMEN
BACKGROUND AND AIMS: Testicular Germ Cell Tumours (TGCTs) are the commonest young adult male cancer, with excellent survival outcomes even with metastatic disease. Chemotherapy, radiotherapy, and surgery are international guideline-dictated standard of care (SOC) treatments for International Germ Cell Cancer Collaborative Group (IGCCCG) "good risk" TGCT, but are associated with significant toxicities. Therapy de-escalation aims to reduce treatment morbidity whilst preserving cure rates, and has been adopted by some centres for stage IIA/B seminoma. Here, we report on the contemporary UK treatment landscape for stage IIA/B seminoma. METHODS: A questionnaire-based survey of NHS England-designated specialist cancer centres hosting supra-regional specialist multi-disciplinary team (sMDT) services (n = 13) as well those within NHS Scotland, NHS Wales and Health and Social Care Northern Ireland. Respondents were asked to order preferences of SOC and therapy de-escalation treatments for stage IIA/B seminoma. RESULTS: We identified significant geographical heterogeneity in treatment preferences. Whilst up to a third of centres have adopted a treatment de-escalation regimen, the majority deliver combination chemotherapy or radiotherapy. CONCLUSION: A wider recognition of UK treatment heterogeneity and consideration of therapy de-escalation strategies at supra-regional sMDTs will increase stage IIA/B seminoma treatment options as part of clinical trials with oncological and quality of life endpoints.
Asunto(s)
Seminoma , Neoplasias Testiculares , Humanos , Masculino , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias , Calidad de Vida , Seminoma/patología , Seminoma/terapia , Neoplasias Testiculares/tratamiento farmacológico , Reino Unido/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Extragonadal germ cell tumors (GCTs) are thought to arise as a result of local transformation of primordial gonadal cells (PGCs) that become misplaced during embryogenesis. With the exception of bilateral testis tumors, metachronous GCT (i.e., occurring at a site classically described for primary GCTs) are rare events. PATIENTS AND METHODS: The clinical, radiological, and molecular data (if available) of patients with metachronous GCT were analyzed. RESULTS: Three Caucasian males were identified: case 1 presented with a pineal germinoma 19 years after a mediastinal seminoma that had been treated with chemotherapy, case 2 presented with a pineal non-seminomatous GCT (NSGCT) that occurred three years after a mediastinal seminoma treated with chemotherapy, and case 3 presented with a mediastinal seminoma concomitant with a suprasellar germinoma that occurred two years after a stage I testicular NSGCT treated exclusively with surgery. None of these patients had a positive family history or disorder of sex development. Molecular data were available for cases 2 and 3. In case 2, a CHEK2 gene biallelic inactivation in the second tumor suggested chemoresistance to cisplatin. This was further confirmed by tumor progression during second-line treatment. In case 3, the molecular analysis revealed different profiles in the three tumors, thus suggesting distinct tumor cell origins. CONCLUSION: These rare cases should alert clinicians of the possibility of multiple GCTs that should not be considered to be relapses. The underlying physiopathology is unknown, but multiple PGC mismigrations is a likely cause. Initial treatment with cisplatin may select chemo-resistant clones, thereby making the subsequent treatment more of a challenge.
Asunto(s)
Terapia Combinada/métodos , Neoplasias de Células Germinales y Embrionarias/diagnóstico por imagen , Neoplasias de Células Germinales y Embrionarias/terapia , Neoplasias Primarias Secundarias/diagnóstico por imagen , Neoplasias Primarias Secundarias/terapia , Adolescente , Adulto , Quinasa de Punto de Control 2/genética , Manejo de la Enfermedad , Resistencia a Antineoplásicos , Humanos , Masculino , Neoplasias del Mediastino/diagnóstico por imagen , Neoplasias del Mediastino/genética , Neoplasias del Mediastino/terapia , Homólogo 1 de la Proteína MutL/genética , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias Primarias Secundarias/genética , Pinealoma/diagnóstico por imagen , Pinealoma/genética , Pinealoma/terapia , Seminoma/diagnóstico por imagen , Seminoma/genética , Seminoma/terapia , Adulto JovenRESUMEN
PURPOSE: We analyzed the oncologic outcomes of men undergoing primary retroperitoneal lymph node dissection and characterized the use of adjuvant chemotherapy and template dissections. MATERIALS AND METHODS: Retrospective review of the Indiana University testis cancer database identified patients who underwent primary retroperitoneal lymph node dissection between January 2007 and December 2017. Patients and providers were contacted to obtain information regarding adjuvant therapy, recurrence and survival. The primary outcome was recurrence-free survival. Kaplan-Meier curves assessed survival differences stratified by pathological stage, template of dissection and use of adjuvant chemotherapy. RESULTS: A total of 274 patients were included in the study. Most men presented with clinical stage I disease (214, 78%). A modified unilateral template was performed in 257 (94%) and bilateral template in 17 (6%). Overall 148 (54%) and 126 (46%) men had pathological stage (PS) I and PS-II disease, respectively. Thirteen patients (10%) with PS-II disease were treated with adjuvant chemotherapy. With a median followup of 55 months only 33 (12%) patients had recurrence. Of the 113 patients with PS-II disease who did not receive chemotherapy 21 (19%) had disease relapse and 81% were cured with surgery alone and never had recurrence. No difference in recurrence-free survival was noted between modified and bilateral template dissections. CONCLUSIONS: The use of adjuvant chemotherapy has been minimal during the last decade. The majority (81%) of men with PS-II disease were cured with retroperitoneal lymph node dissection alone and were able to avoid chemotherapy. Modified unilateral template dissection provided excellent oncologic control while minimizing morbidity.
Asunto(s)
Quimioterapia Adyuvante/estadística & datos numéricos , Escisión del Ganglio Linfático , Espacio Retroperitoneal/cirugía , Neoplasias Testiculares/patología , Neoplasias Testiculares/terapia , Adulto , Estudios de Seguimiento , Humanos , Masculino , Recurrencia Local de Neoplasia , Neoplasias de Células Germinales y Embrionarias/mortalidad , Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias de Células Germinales y Embrionarias/terapia , Espacio Retroperitoneal/patología , Estudios Retrospectivos , Seminoma/mortalidad , Seminoma/patología , Seminoma/terapia , Teratoma/mortalidad , Teratoma/patología , Teratoma/terapia , Neoplasias Testiculares/mortalidadRESUMEN
PURPOSE: Robotic assisted retroperitoneal lymph node dissection in patients with testicular cancer is controversial. Lately, unusual recurrence patterns with adverse outcomes after robotic assisted retroperitoneal lymph node dissection have been published. In this report we determine the feasibility, safety and early oncologic outcome of robotic assisted retroperitoneal lymph node dissection in patients with small volume metastatic testicular cancer. MATERIALS AND METHODS: We retrospectively evaluated 27 consecutive patients with small volume metastatic testicular cancer (October 2010 to November 2019) who underwent robotic assisted retroperitoneal lymph node dissection (unilateral modified template). Intraoperative and postoperative complications as well as early oncologic outcomes are reported. Surgery was performed in the primary metastatic setting in 22 (81%), post-chemotherapy in 4 (15%) and for late relapse in 1 patient (4%). Initial clinical stage was IIA for 14 (52%), IIB for 12 (43%) and III for 1 (4%) patient. RESULTS: Median operative time, blood loss and length of hospital stay were 175 minutes, 50 ml and 4 days, respectively. Expectedly, viable tumor was found in 21/27 patients (78%) and 6 patients (22%) showed fibrosis, necrosis or no tumor. Overall 3 (11%) patients experienced intraoperative (Satava II) and 1 (4%) postoperative (Clavien-Dindo IIIb) complications, respectively. Median followup was 16.5 months (3-69), and 3 (11%) patients experienced relapse outside of the surgical field after 12, 22 and 36 months. CONCLUSIONS: In highly selected patients with low volume metastatic testicular cancer robotic assisted retroperitoneal lymph node dissection may be indicated, and appears to be technically feasible and comparable with open surgery in terms of complications and early oncologic safety. Prospective data collection in larger series is necessary to clarify the role and specific indications of this approach.
Asunto(s)
Escisión del Ganglio Linfático/efectos adversos , Metástasis Linfática/terapia , Procedimientos Quirúrgicos Robotizados/efectos adversos , Seminoma/terapia , Neoplasias Testiculares/terapia , Adulto , Anciano , Pérdida de Sangre Quirúrgica/estadística & datos numéricos , Quimioterapia Adyuvante , Estudios de Factibilidad , Estudios de Seguimiento , Humanos , Tiempo de Internación/estadística & datos numéricos , Escisión del Ganglio Linfático/métodos , Ganglios Linfáticos/patología , Ganglios Linfáticos/cirugía , Metástasis Linfática/patología , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante/métodos , Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/prevención & control , Estadificación de Neoplasias , Tempo Operativo , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Estudios Prospectivos , Espacio Retroperitoneal/patología , Espacio Retroperitoneal/cirugía , Estudios Retrospectivos , Seminoma/epidemiología , Seminoma/secundario , Neoplasias Testiculares/epidemiología , Neoplasias Testiculares/patología , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: To validate the utility of the chemokine ligand 12 (CXCL12) as prognostic marker in patients with localized and metastatic germ cell tumors (GCT). METHODS: CXCL12 expression was analyzed on a tissue microarray consisting of 750 tissue cores of different histological tumor components, Germ cell neoplasia in situ (GCNIS) and adjacent normal tissue of 263 testicular cancer patients using a semi-quantitative score. The association between CXCL12 expression and recurrence-free survival (RFS) as well as overall survival (OS) was assessed using Kaplan-Meier curves with log-rank tests. RESULTS: CXCL12 expression was absent in all seminomas but was found in 52 of 99 (52.5%) non-seminomas. Follow-up was available for 260 patients of which 36 (13.8%) recurred. In patients with stage 1 non-seminoma GCT, CXCL12 expression was not associated with higher risk of disease recurrence (p = 0.270). In contrast, post chemotherapy RFS of patients with metastatic non-seminoma and positive CXCL12 expression was significantly shorter compared to CXCL12 negative patients (p = 0.003). OS differences were not statistically different between patients with CXCL12 positive or negative tumors for either localized or metastatic disease. CONCLUSIONS: CXCL12 is almost exclusively expressed in non-seminoma. Pure seminoma, GCNIS and adjacent normal testicular tissue are CXCL12 negative. Our analysis suggests that patients with metastatic disease and a CXCL12-positive non-seminoma are at higher risk for disease recurrence after first-line chemotherapy and might thus be candidates for more intensive treatment and/or closer follow-up.
Asunto(s)
Quimiocina CXCL12/genética , Quimiocina CXCL12/metabolismo , Recurrencia Local de Neoplasia , Neoplasias de Células Germinales y Embrionarias/fisiopatología , Neoplasias Testiculares/fisiopatología , Adolescente , Adulto , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Humanos , Masculino , Neoplasias de Células Germinales y Embrionarias/genética , Neoplasias de Células Germinales y Embrionarias/metabolismo , Pronóstico , Seminoma/diagnóstico , Seminoma/fisiopatología , Seminoma/terapia , Análisis de Supervivencia , Neoplasias Testiculares/genética , Neoplasias Testiculares/metabolismo , Adulto JovenRESUMEN
Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment.
Asunto(s)
Biomarcadores de Tumor/análisis , Neoplasias Pulmonares/mortalidad , Seminoma/clasificación , Neoplasias Testiculares/clasificación , Supervivencia sin Enfermedad , Humanos , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Masculino , Estadificación de Neoplasias , Pronóstico , Medición de Riesgo , Seminoma/mortalidad , Seminoma/secundario , Seminoma/terapia , Neoplasias Testiculares/mortalidad , Neoplasias Testiculares/secundario , Neoplasias Testiculares/terapia , Testículo/patologíaRESUMEN
Testicular cancer has excellent cure rates; however, poor guideline adherence can lead to inappropriate management, with a detrimental effect on outcomes. Therefore, we aimed to investigate the current patterns of care for testicular cancer patients and to evaluate guideline adherence. A 19-item survey was distributed among German urologists between September 2015 and September 2016. The response rate was 45% (411/920). Staging imaging of the chest was performed by computed tomography (CT) in 85.5% and X-ray in 17.7%, and for the abdomen, by CT in 83.7% and by magnetic resonance imaging (MRI) in 21.1%. Areas of discrepancy with respect to guideline recommendations included underuse of MRI and infrequent follow-up examinations for changes in the cardiovascular, endocrine, neurological, and pulmonary systems, in addition to psychological burden. Further deviations of reported routine procedures from guideline recommendations were identified in the fields of active surveillance in Stage I seminoma, contralateral biopsies (63.1% overuse) and cryopreservation (19.2% underuse). Moreover, we found that hospital-based clinicians and younger specialists, with ≤5 years of practice following board certification, perform a more accurate and thorough follow-up. German urologists show relatively strong guideline adherence in staging patterns. Significant improvements are necessary in the following areas: recommending cryopreservation, imaging modalities and accurate follow-up examinations with a focus on late toxicities.
Asunto(s)
Preservación de la Fertilidad , Adhesión a Directriz , Neoplasias de Células Germinales y Embrionarias/terapia , Guías de Práctica Clínica como Asunto , Preservación de Semen , Neoplasias Testiculares/terapia , Urología/normas , Espera Vigilante , Cuidados Posteriores , Factores de Edad , Biopsia , Criopreservación , Femenino , Alemania , Humanos , Imagen por Resonancia Magnética , Masculino , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/patología , Orquiectomía , Radiografía Abdominal , Radiografía Torácica , Seminoma/patología , Seminoma/terapia , Neoplasias Testiculares/patología , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: To investigate the clinical and histopathologic features of testicular seminoma with syncytoplasmic trophoblastic components. METHODS: Using light microscopic staining, we analyzed the clinical and histopathologic characteristics, diagnosis, differential diagnosis and prognosis of 3 cases of testicular seminoma with syncytoplasmic trophoblastic components, and reviewed the relevant literature. RESULTS: All the 3 cases were typical seminoma with syncytiotrophoblastic giant cells. Immunohistochemistry showed strong expressions of CD117 OCT-4, SALL4 and PLAP in diffuse tumor cells, and that of hCG in syncytiotrophoblastic cells. Continuous monitoring and consultation exhibited normal levels of serum ß-hCG in all the cases after postoperative chemotherapy. CONCLUSIONS: Testicular seminoma with syncytiotrophoblastic giant cells and increased serum ß-hCG is a rare subtype, which occurs mostly in young people, sensitive to chemotherapy postoperatively and with a relatively good prognosis.
Asunto(s)
Seminoma/diagnóstico , Neoplasias Testiculares/diagnóstico , Trofoblastos/citología , Gonadotropina Coriónica/sangre , Células Gigantes/citología , Humanos , Inmunohistoquímica , Masculino , Pronóstico , Seminoma/terapia , Neoplasias Testiculares/terapiaRESUMEN
PURPOSE OF REVIEW: In the present review, we summarize the recent developments in the management of germ cell tumors (GCTs). RECENT FINDINGS: Treatment-related acute and late-onset toxicity remains a key challenge in the management of GCTs, with recent evidence showing that the adverse health outcomes of etoposide and cisplatin for four cycles in comparison to bleomycin, etoposide, and cisplatin for three cycles appear to be similar. Recent data showed that multidisciplinary clinic approach and management in experienced academic centers were associated with improved overall survival in GCT patients. There are currently multiple conventional-dose chemotherapy options for salvage therapy in patients with refractory or recurrent disease. In addition, more efficacious high-dose chemotherapy regimens continue to be developed. The role of salvage conventional-dose chemotherapy versus high-dose chemotherapy is currently being investigated prospectively. Recent reports suggested that brentuximab vedotin could be a potential salvage option for cluster of differentiation 30 positive refractory GCTs. On the other hand the results of the first phase II clinical trial investigating pembrolizumab in refractory GCTs were disappointing showing no clinical activity.Finally, deep exploration of the immune profile of GCTs using immunohistochemistry and gene expression profiling has identified that advanced GCT stage was associated with decreased T-cell and Natural killer-cell signatures, whereas T regulatory, neutrophil, mast cell, and macrophage signatures increased with advanced stage. Even though these results indicated that activated T-cell infiltration correlated with seminoma histology and good prognosis, and could be used in the future as a biomarker, this approach needs to be validated in a large cohort. SUMMARY: Remaining challenges to be addressed include minimizing therapeutic toxicity, and improving outcomes in patients with refractory/recurrent GCTs.
Asunto(s)
Neoplasias de Células Germinales y Embrionarias/terapia , Seminoma/terapia , Neoplasias Testiculares/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Humanos , Masculino , Neoplasias de Células Germinales y Embrionarias/inmunología , Ensayos Clínicos Controlados Aleatorios como Asunto , Terapia Recuperativa , Seminoma/inmunología , Neoplasias Testiculares/genética , Neoplasias Testiculares/inmunologíaRESUMEN
PURPOSE: We report the safety of surveillance of small testicular masses incidentally discovered during evaluation of male infertility. MATERIALS AND METHODS: We retrospectively reviewed a prospectively collected database to identify patients with male infertility found to have incidental small testicular masses (hypoechoic lesions less than 10 mm) on scrotal ultrasound. The men were offered close surveillance with interval imaging and office followup. Patient and imaging characteristics were collected to compare the surveillance and surgical groups with additional comparisons between benign and malignant pathologies to elucidate predictors of underlying malignancy. RESULTS: Of 4,088 men in whom scrotal ultrasound was completed for male infertility evaluation 120 (2.9%) were found to have a subcentimeter testicular mass. Average followup was 1.30 years (range 0.1 to 16.9). A total of 18 men (15%) proceeded to extirpative surgery while 102 remained on surveillance at last followup. In those with at least 1 month of followup the mean lesion growth rate was -0.01 mm per year. Reasons for surgery included testicular exploration for infertility, mass growth, positive tumor markers, history of testis cancer, concerning imaging characteristics and patient choice. Six of the 18 men who underwent surgery were found to have malignancy, which was seminoma in all. All malignant lesions were greater than 5 mm on initial imaging and demonstrated vascularity, although size and vascularity were not significantly different from those of benign lesions on final pathology findings. No patients demonstrated advanced or recurrent disease. CONCLUSIONS: Small testicular masses are not uncommon, especially in the infertile male population. Most of these masses do not show significant growth during long-term evaluation and can be safely surveilled with close followup.
Asunto(s)
Infertilidad Masculina/diagnóstico por imagen , Seminoma/diagnóstico por imagen , Neoplasias Testiculares/diagnóstico por imagen , Adulto , Estudios de Seguimiento , Humanos , Hallazgos Incidentales , Infertilidad Masculina/complicaciones , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Seminoma/complicaciones , Seminoma/epidemiología , Seminoma/terapia , Neoplasias Testiculares/complicaciones , Neoplasias Testiculares/epidemiología , Neoplasias Testiculares/terapia , Ultrasonografía , Espera VigilanteRESUMEN
PURPOSE OF REVIEW: Germ cell testicular tumors (GCTTs) are the most common malignancy in young men, and the incidence is increasing worldwide. Most patients present with clinical stage I (CS1) disease, and active surveillance is being increasingly adopted as the preferred initial treatment modality. In this review, we describe the concept of conditional risk of relapse (CRR), an evolving risk estimate for CS1 GCTT patients on active surveillance who have not relapsed. RECENT FINDINGS: At diagnosis, patients are often counseled about their initial risk of relapse based on known risk factors present at diagnosis. However, the risk estimate becomes less informative in patients who have survived a period of time without experiencing relapse. CRR, on the other contrary, provides specific information on a patient's evolving risk of relapse over time. This dynamic estimate can be used to tailor surveillance protocols based on future risk of relapse within risk subgroups. SUMMARY: Implementation of CRR in patients on active surveillance can reduce the burden of follow-up, the number of physician visits and tests, and lower costs for the healthcare system. Finally, CRR estimates provide patients with a meaningful, evolving risk estimate, and may help reassure patients and reduce potential anxiety while continuing active surveillance.
Asunto(s)
Recurrencia Local de Neoplasia/epidemiología , Neoplasias de Células Germinales y Embrionarias/terapia , Seminoma/terapia , Neoplasias Testiculares/terapia , Quimioterapia Adyuvante , Humanos , Escisión del Ganglio Linfático , Masculino , Estadificación de Neoplasias , Orquiectomía , Radioterapia Adyuvante , Espacio Retroperitoneal , Riesgo , Seminoma/patología , Neoplasias Testiculares/patología , Espera VigilanteRESUMEN
PURPOSE OF REVIEW: Testicular germ cell tumour (TGCT) is a common malignancy among young men. There is controversy regarding the best approach for patients with clinical stage I disease due to rates of relapse with active surveillance in contrast to overtreatment with adjuvant therapy. The aim of this review is to describe the role of prognostic factors in this setting. RECENT FINDINGS: Molecular prognostic factors have been described as a possible future aid to clinical and histologic features in the approach of patients with clinical stage I germ cell tumours. SUMMARY: Prognostic factors currently available are not accurate enough and may lead to overtreatment. However, though active surveillance has shown long-term survival near to 100% in the management of clinical stage I germ cell tumours, there is a significant percentage of patients with occult metastatic disease, who benefit from adjuvant therapy. In light of these data, future research is needed to better define high-risk patients for relapse, taking into account molecular markers recently reported.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/metabolismo , Carboplatino/uso terapéutico , Neoplasias de Células Germinales y Embrionarias/terapia , Seminoma/terapia , Neoplasias Testiculares/terapia , Bleomicina/uso terapéutico , Quimioterapia Adyuvante , Cisplatino/uso terapéutico , Etopósido/uso terapéutico , Humanos , Escisión del Ganglio Linfático , Ganglios Linfáticos/patología , Masculino , Invasividad Neoplásica , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/metabolismo , Neoplasias de Células Germinales y Embrionarias/patología , Orquiectomía , Pronóstico , Radioterapia Adyuvante , Espacio Retroperitoneal , Seminoma/metabolismo , Seminoma/patología , Neoplasias Testiculares/metabolismo , Neoplasias Testiculares/patologíaRESUMEN
Testicular cancer is a rare urological malignancy with high cure rate. The development of highly effective systemic treatment regimens along with advances in surgical treatment of advanced disease has led to continued improvement in outcomes. Patients with testicular cancer who are treated following the treatment guideline mostly achieved high quality of life and long-term survival. However, patients who were identified as having non-guideline directed care were at significantly higher risk of relapse. In this book chapter, we introduce in depth the modern management of testicular cancer, including diagnosis, staging and risk stratification, treatment strategies of seminoma and non-seminoma germ cell tumors, follow-up protocols, and salvage treatment for disease relapse. We also review new studies and updates on medical and surgical management of advanced testicular cancer.
Asunto(s)
Neoplasias de Células Germinales y Embrionarias , Seminoma , Neoplasias Testiculares , Humanos , Masculino , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/terapia , Calidad de Vida , Seminoma/terapia , Neoplasias Testiculares/terapiaRESUMEN
INTRODUCTION: Testicular cancer is a rare disease, most commonly seen in young adults. It represents 1% of solid cancers in men. Inferior vena cava (IVC) thrombosis remains a rare complication of testicular cancer and is often associated with a high risk of pulmonary embolism (PE). CASE REPORT: The authors report a case of a 26-year-old man presenting with advanced testicular cancer, left-sided retroperitoneal metastasis and parietal infiltration of the IVC complicated with thrombosis of the left iliac vein and the IVC, both responsible for PE. DISCUSSION: A multidisciplinary management which included curative excision of the lesions, placement of a temporary IVC filter and adjuvant chemotherapy permitted an optimal approach. No complications occurred and the post-operative healing was uneventful. No recurrences were observed on the long-term follow-up. CONCLUSIONS: IVC Thrombosis is a rare complication that should be taken into consideration when diagnosing testicular cancer. Prompt diagnosis is crucial to minimize the risk of PE which can be life-threatening.
Asunto(s)
Seminoma/terapia , Neoplasias Testiculares/terapia , Trombosis de la Vena/etiología , Terapia Combinada , Humanos , Masculino , Flebografía , Seminoma/complicaciones , Seminoma/diagnóstico , Neoplasias Testiculares/complicaciones , Neoplasias Testiculares/diagnóstico , Tomografía Computarizada por Rayos X , Trombosis de la Vena/diagnóstico , Trombosis de la Vena/terapia , Adulto JovenRESUMEN
A 78-year-old man presented with swelling of para-aortic and left iliac lymph nodes (LNs). He had undergone left high orchiectomy 10 years ago. He was diagnosed with stage I seminoma, and was managed with active surveillance. Eight years later, the follow-up computed tomography (CT) revealed para-aortic LN swelling, but the patient refused further treatment. He complained of left lower extremity edema 10 years after orchiectomy. CT showed enlargement of both LNs, especially, diameter of left iliac lymph nodes was up to 9 cm. He was referred to our hospital. LDH was slightly increased to 261 IU/1, but α-fetoprotein, and total and free beta human chorionic gonadotropin were within normal limits. Results of pathological review of the testicular tumor was also seminoma. The treatment with etoposide and cisplatin (EP) was started under the diagnosis of late relapse of seminoma. However, CT after 1 course of EP showed no shrinkage of LN metastases. At this time, soluble interleukin-2 receptor (sIL-2R) was elevated up to 5,090 U/ml (normal range: 613 U/ml). Needle biopsy from pelvic LN was performed on suspicion of metachronous malignant lymphoma. The pathological diagnosis was mantle cell lymphoma. The patient was transferred to the department of hematology, and treated successfully with rituximab and bendamustine. When LN swelling is seen after long-term active surveillance, there is a possibility of late relapse. However, metachronous malignant lymphoma also should be considered in an elderly patient.
Asunto(s)
Linfoma de Células del Manto , Neoplasias Primarias Secundarias , Seminoma , Neoplasias Testiculares , Anciano , Humanos , Linfoma de Células del Manto/diagnóstico , Linfoma de Células del Manto/terapia , Masculino , Neoplasias Primarias Secundarias/diagnóstico , Neoplasias Primarias Secundarias/terapia , Orquiectomía , Seminoma/diagnóstico , Seminoma/terapia , Neoplasias Testiculares/diagnóstico , Neoplasias Testiculares/terapia , alfa-FetoproteínasRESUMEN
OBJECTIVE: To investigate the clinical features, diagnosis, treatment and prognosis of testicular mixed germ cell tumors (TMGCT). METHODS: This retrospective study included 27 cases (2 children and 25 adults) of TMGCT confirmed surgically and pathologically in our hospital from December 2007 to December 2012. The patients' ranged in the age of onset from 7 months to 63 years, averaging at 29.5 years. We analyzed the clinical data and reviewed the related literature. RESULTS: At pathological examination, the TMGCTs displayed a variety of subtypes, including 13 cases of yolk sac tumor (48.1%), 13 cases of seminoma (48.1%), 18 cases of embryonal carcinoma (66.7%), 4 cases of choriocarcinoma (14.8%) and 17 cases of teratoma (63.0%). Of the total number of cases, 15 (55.6%) contained two different germ cell histological elements, 11 (40.7%) contained three, and 1 (3.7%) contained four; 18 cases (66.7%) were in stage â , 6 (22.2%) in stage â ¡, and 3 (11.1%) in stage â ¢. All the patients underwent radical orchiectomy and, in addition, retroperitoneal lymph node dissection (RPLND) + BEP chemotherapy was administered for 3 cases of stage â ¡ and 1 case of stage â ¢. Three cases of stage â ¡ and 2 cases of stage â ¢ refused RPLND and 1 case of stage â ¢ refused chemotherapy. A 27ï¼49-month (mean 30 months) follow-up was completed for 21 of the patients, during which retroperitoneal metastasis was found in 3 cases of stage â and 2 cases of stage â ¡, who again received RPLND+BEP and experienced no more recurrence. One case of stage â ¢ refused both RPLND and chemotherapy and died at 12 months. CONCLUSIONS: TMGCT is a rare carcinoma with atypical clinical features, mostly comprising two or three different germ cell histological elements. Comprehensive treatment of RPLND combined with BEP chemotherapy may achieve a high survival rate and reduce recurrence for most of the patients with TMGCT of stage â ¡ or above.